Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Johnson & Johnson | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Johnson & Johnson

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Johnson & Johnson

4Q Revenues: $13.7 billion (+8.5%)

4Q Earnings: $2.2 billion (+3.5%)

FY Revenues: $53.3 billion (+5.6%)

FY Earnings: $11 billion (+10%)

Comments: Worldwide pharmaceutical sales were $23.3 billion for the year, up 4%. In the quarter, both domestic and international sales increased 4%. For the year, domestic sales were up 6% and international sales were up 11%. Sales growth reflects the strong performance of Risperdal, Remicade, Topamax, Velcade and Concerta. Earnings for the quarter include an after-tax charge for in-process R&D of $217 million associated with the acquisition of Pfizer Consumer Healthcare.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters